Allergic rhinitis is the inflammatory disease distinguished by the symptoms of runny nose – rhinorrhoea, nasal congestion, watery eyes, sneezing and itching of the nose and visual symptoms of red – itching – burning and watery eyes. Such symptoms usually occur after exposure to allergens like mold spores and pollens that cause SAR or whole year round allergens like dust mites or animal dander that cause PAR.

Allermist or Avamys is an anti-allergic drug especially formulated for the intranasal treatment of significantly improved symptoms of Seasonal and Perennial Allergic Rhinitis by using the effective ingredient called Fluticasone Furoate, after having conducted the extensive clinical studies by the world leaders in pharmaceuticals GlaxoSmithKline – GSK. The medicine is the improved empathy intranasal corticosteroid with its proposed brand name of Allermist for the United States markets and Avamys for the European markets.   

The safety and efficacy factors of Allermist have been assessed in seven clinical trials with 2,555 patients comprising of adults and children with 2 years and more age having symptoms of SAR – Seasonal Allergic Rhinitis and PAR – Perennial Allergic Rhinitis. The remarkable improvement was noticed in the patients who used Allermist medication in the range of their nasal symptoms as compared to those who took the placebo. For the adult patients having SAR, besides improvement in their nasal symptoms, the use of medicine was also every time related with considerable progress in visual symptoms that include: watery or itchy eyes.

Allermist is developed after ergonomic testing and then dispensed by using the novel nasal device that is typically designed keeping the convenience of the patient in mind. The product is unscented and totally alcohol free and has truly negligible or perhaps no after taste at all.